We are excited to announce that the repository will soon undergo an upgrade, featuring a new look and feel along with several enhanced features to improve your experience. Please be on the lookout for further updates and announcements regarding the launch date. We appreciate your support and look forward to unveiling the improved platform soon.
dc.contributor.author | Dreyer, Greta![]() |
|
dc.contributor.author | Visser, Cathy![]() |
|
dc.contributor.author | Dreyer, Gerrit Jan![]() |
|
dc.contributor.author | Botha, Matthys H.![]() |
|
dc.contributor.author | Van der Merwe, Frederick H.![]() |
|
dc.contributor.author | Richter, Karin Louise![]() |
|
dc.contributor.author | Snyman, Leon Cornelius![]() |
|
dc.date.accessioned | 2024-10-25T08:16:55Z | |
dc.date.available | 2024-10-25T08:16:55Z | |
dc.date.issued | 2024-05 | |
dc.description | AVAILABILITY OF DATA AND MATERIALS : Cited references and supplementary data files provide data in support of the findings and further data will be made available upon reasonable request. | en_US |
dc.description.abstract | BACKGROUND : Cervical cancer screening strategies should ideally be informed by population-specific data. Strategies recommended for secondary prevention, are often inadequately studied in populations with high cervical disease burdens. This report describes the test performance measured against CIN2 + /CIN3 + histology in HIV-positive women (HPW) and HIV-negative women (HNW) with the aim to determine the most effective strategies to identify South African women at risk. METHODS : Primary screening using visual inspection, cytology and HPV DNA (cobas®) was performed in two South African provinces on 456 HPW and 639 HNW participating in the multicentric DiaVACCS trial. Histology was obtained for 91.7% screen-positive and 42.7% screen-negative participants, and unavailable histology was determined by multiple imputation to adjust for verification bias. Cross-sectional test performance was calculated for single and combination test strategies with and without intermediate risk categories using different cut-offs. Minimum acceptability for sensitivity and specificity, treatment and follow-up numbers were considered to evaluate strategies. RESULTS : The only single test to reach acceptability in HPW was cytology (LSIL) [sensitivity 71.2%; specificity 90.5%; treatment 33.4%]; in HNW only HPV (hr) qualified [sensitivity 68.2%; specificity 85.2%; treatment 23.5%]. The universally best performing strategy which also resulted in smaller treatment numbers without intermediate risk group was primary HPV(hr), with treatment of both HPV(16/18) and cytology (ASCUS +) [HPW: sensitivity 73.6%; specificity 89.7%; treatment 34.7%. HNW: sensitivity 59.1%; specificity 93.6%; treatment 13.9%]. DNA testing for hrHPV (any) and hrHPV (16/18) was the best universally acceptable strategy with an intermediate risk category (early follow-up) in HPW [sensitivity 82.1%; specificity 96.4%; treatment 17.1%; follow-up 31.4%] and HNW [sensitivity 68.2%; specificity 96.7%; treatment 7.6%; follow-up 15.9%]. In comparison, using both HPV (16/18) and cytology (ASCUS +) as secondary tests in hrHPV positive women, decreased follow-up [HPW 13.8%, HNW 9.6%], but increased treatment [HPW 34.7%, HNW 13.9%]. CONCLUSION : Using hrHPV (any) as primary and both HPV16/18 and cytology as secondary tests, was universally acceptable without an intermediate risk group. Strategies with follow-up groups improved screening performance with smaller treatment numbers, but with effective management of the intermediate risk group as prerequisite. | en_US |
dc.description.department | Medical Virology | en_US |
dc.description.department | Obstetrics and Gynaecology | en_US |
dc.description.librarian | hj2024 | en_US |
dc.description.sdg | SDG-03:Good heatlh and well-being | en_US |
dc.description.sponsorship | Roche Diagnostics Division, First for Women Foundation, Fuchs Foundation. Infrastructure and financial support: Gynaecologic Oncology Units of Stellenbosch University and University of Pretoria. | en_US |
dc.description.uri | https://infectagentscancer.biomedcentral.com/ | en_US |
dc.identifier.citation | Dreyer, G., Visser, C., Dreyer, G.J. et al. The performance of single and combination test strategies using visual inspection, cytology, high-risk HPV DNA and HPV16/18 to screen South African women with and without HIV-infection. Infectious Agents and Cancer 19, 22 (2024). https://doi.org/10.1186/s13027-024-00586-3. | en_US |
dc.identifier.issn | 1750-9378 (online) | |
dc.identifier.other | 10.1186/s13027-024-00586-3 | |
dc.identifier.uri | http://hdl.handle.net/2263/98773 | |
dc.language.iso | en | en_US |
dc.publisher | BMC | en_US |
dc.rights | © The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License. | en_US |
dc.subject | Triage test | en_US |
dc.subject | Human immunodeficiency virus (HIV) | en_US |
dc.subject | Cervical cancer | en_US |
dc.subject | Cervical cancer screening strategy | en_US |
dc.subject | HIV-infection | en_US |
dc.subject | Screening test performance | en_US |
dc.subject | SDG-03: Good health and well-being | en_US |
dc.title | The performance of single and combination test strategies using visual inspection, cytology, high-risk HPV DNA and HPV16/18 to screen South African women with and without HIV-infection | en_US |
dc.type | Article | en_US |